BioClarus Insights

Liposomal delivery: when usable yield changes the investment case

Original research published

Conceptual illustration of an unlabelled vial beside an enlarged liposome containing two differently colored payloads in a manufacturing laboratory. Not microscopy or a scale drawing.

A lower calculated cost per vial is not necessarily cash saved. Clarus Review uses liposomal delivery to explore the distinction between reproducing an evidence-generating product, increasing usable output and creating an economically useful manufacturing improvement.

The historical product example and the article’s financial exercise serve different purposes. Clinical evidence belongs to the tested formulation and population; it does not establish a universal benefit of liposomes. The model’s batch costs, yields, quality-release assumptions and timetable are hypothetical. They are not reported manufacturing data for Vyxeos or a proposed clinical dosing method.

The exercise follows output through production and subsequent quality disposition. A denominator that counts only successful runs can hide losses elsewhere. An apparent unit-cost improvement also needs a demand test: if extra output is not needed and attempted batches cannot be reduced, the accounting allocation may improve without releasing cash. Whole-batch scheduling, shelf life and release timing can change the decision.

The executive implication is to evaluate technical and investment success separately. A process change needs evidence that it preserves the relevant product properties, a realistic supply calendar and a demand-linked account of avoidable costs. The full article supplies the scenario assumptions and limitations; it does not recommend a manufacturing specification, imply interchangeability or claim actual client savings.

Read the full Clarus Biotech Review article

Sources

  1. pmc.ncbi.nlm.nih.gov/articles/PMC6127025/
  2. www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-certain-types-poor-prognosis-acute-myeloid-leukemia
  3. www.accessdata.fda.gov/drugsatfda_docs/label/2026/209401s018lbl.pdf
  4. www.fda.gov/media/70837/download

Deep Domain Expertise Across Therapeutic Areas